Search results
5 days ago · About Regeneron and Sanofi’s COPD Clinical Research Program Regeneron and Sanofi are motivated to transform the treatment paradigm of COPD by examining the role different types of inflammation play in the disease progression through Dupixent, a first-in-class biologic, and the investigation of itepekimab.
3 days ago · Sanofi SNY and partner Regeneron REGN announced that the FDA has approved their blockbuster drug, Dupixent, for its sixth indication — chronic obstructive pulmonary disease (COPD) — in the ...
3 days ago · TARRYTOWN, N.Y. and PARIS, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the National Medical Products Administration (NMPA) in China has approved Dupixent ® (dupilumab) as an add-on maintenance treatment for adults with ...
2 days ago · Sanofi is one of the largest pharmaceutical companies in the world, with a rich history of innovation that dates back over 100 years. Its history includes some of the major scientific advances of...
6 days ago · The FDA has expanded the label of Regeneron and Sanofi's Dupixent to treat COPD. Dupixent becomes the first biologic for COPD patients in the U.S.
1 day ago · Triveni Bio has secured $115m in a Series B funding round to advance its preclinical antibody candidates for immunological and inflammatory diseases. The round was led by Goldman Sachs Alternatives and included support from both returning and new investors such as Fidelity Management & Research Company and Deep Track Capital.
6 days ago · Regeneron and Sanofi are motivated to transform the treatment paradigm of COPD by examining the role different types of inflammation play in the disease progression through the investigation of ...
